MEP19408A - Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same - Google Patents

Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same

Info

Publication number
MEP19408A
MEP19408A MEP-194/08A MEP19408A MEP19408A ME P19408 A MEP19408 A ME P19408A ME P19408 A MEP19408 A ME P19408A ME P19408 A MEP19408 A ME P19408A
Authority
ME
Montenegro
Prior art keywords
compositions
active ingredient
preparing
biodegradable polymer
preparation
Prior art date
Application number
MEP-194/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Rachel S Kohn
Stephen J Hanley
Stephen J Comiskey
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of MEP19408A publication Critical patent/MEP19408A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biological Depolymerization Polymers (AREA)
MEP-194/08A 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same MEP19408A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21298698A 1998-12-16 1998-12-16
PCT/US1999/027705 WO2000035423A1 (en) 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
YUP-414/01A RS50123B (sr) 1998-12-16 1999-11-22 Antagonist serotonin receptora inkapsuliran u biorazgradivom polimeru i postupak njegovog dobijanja

Publications (1)

Publication Number Publication Date
MEP19408A true MEP19408A (en) 2010-06-10

Family

ID=22793267

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-194/08A MEP19408A (en) 1998-12-16 1999-11-22 Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
MEP-2008-194A ME00066B (me) 1998-12-16 1999-11-22 Antagonist serotonin receptora inkapsuliran u biorazgradivom polimeru i postupak njegovog dobijanja

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-2008-194A ME00066B (me) 1998-12-16 1999-11-22 Antagonist serotonin receptora inkapsuliran u biorazgradivom polimeru i postupak njegovog dobijanja

Country Status (35)

Country Link
EP (1) EP1140026B1 (es)
JP (1) JP4759141B2 (es)
KR (1) KR100707710B1 (es)
CN (1) CN1195497C (es)
AP (1) AP1769A (es)
AR (1) AR021652A1 (es)
AT (1) ATE303795T1 (es)
AU (1) AU770673B2 (es)
BG (1) BG65500B1 (es)
BR (1) BR9916276A (es)
CA (1) CA2355077C (es)
CR (1) CR6424A (es)
CZ (1) CZ301947B6 (es)
DE (1) DE69927177T2 (es)
DK (1) DK1140026T3 (es)
EA (1) EA004502B1 (es)
EE (1) EE200100314A (es)
ES (1) ES2245128T3 (es)
HK (1) HK1041645B (es)
HR (1) HRP20010446A2 (es)
HU (1) HU226586B1 (es)
ID (1) ID28909A (es)
IL (2) IL143761A0 (es)
ME (2) MEP19408A (es)
NO (1) NO20012981L (es)
NZ (1) NZ511962A (es)
OA (1) OA11728A (es)
PL (1) PL196822B1 (es)
RS (1) RS50123B (es)
SK (1) SK285812B6 (es)
TR (1) TR200101759T2 (es)
TW (1) TWI221418B (es)
UA (1) UA73101C2 (es)
WO (1) WO2000035423A1 (es)
ZA (1) ZA200104899B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061932A1 (de) * 2000-12-13 2002-10-24 Pharmatech Gmbh Wirkstoffhaltige Mikropartikel und Verfahren zur Herstellung der Mikropartikel durch Abrasion
WO2002075273A2 (en) * 2001-03-20 2002-09-26 Euroscreen S.A. Screening, diagnostic and/or dosage method and device of an agonist and/or antagonist for a calcium-coupled receptor
US8501056B2 (en) * 2001-05-23 2013-08-06 Hexal Ag Homogenized product for implants and microparticles
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US8691277B2 (en) * 2004-09-21 2014-04-08 Shandong Luye Pharmaceutical Co., Ltd. Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
BRPI0913724B8 (pt) * 2008-09-18 2021-05-25 Purdue Pharma Lp formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
US20100291214A1 (en) * 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
WO2010151746A2 (en) * 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20160193151A1 (en) * 2015-01-06 2016-07-07 Maria Del Pilar Noriega Escobar Dosage form incorporating an amorphous drug solid solution
EP4084607A4 (en) * 2019-12-31 2023-06-21 Wanka Tanka Ltd. EXTENDED RELEASE PLASTIC FORMULATION

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
CH679207A5 (es) * 1989-07-28 1992-01-15 Debiopharm Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
WO1991017772A1 (en) * 1990-05-16 1991-11-28 Southern Research Institute Controlled release dopamine and its use to stimulate nerve fiber growth
CA2083698C (en) * 1990-06-01 1997-11-04 Albert A. Carr (+)-alpha-(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
WO1992018106A1 (fr) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US5505963A (en) * 1993-04-07 1996-04-09 Schwartz Pharma Ag Slow release pharmaceutical preparation
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法

Also Published As

Publication number Publication date
CR6424A (es) 2004-02-26
WO2000035423A9 (en) 2002-08-22
ME00066B (me) 2010-06-10
TR200101759T2 (tr) 2001-12-21
SK8282001A3 (en) 2001-11-06
DK1140026T3 (da) 2006-01-02
EA200100551A1 (ru) 2001-10-22
HUP0105048A3 (en) 2002-09-30
SK285812B6 (sk) 2007-08-02
ID28909A (id) 2001-07-12
WO2000035423A1 (en) 2000-06-22
AP2001002198A0 (en) 2001-09-30
EE200100314A (et) 2002-08-15
RS50123B (sr) 2009-03-25
KR20010082359A (ko) 2001-08-29
ATE303795T1 (de) 2005-09-15
CA2355077A1 (en) 2000-06-22
CZ301947B6 (cs) 2010-08-11
AU1742500A (en) 2000-07-03
AR021652A1 (es) 2002-07-31
NZ511962A (en) 2003-06-30
ES2245128T3 (es) 2005-12-16
CN1330536A (zh) 2002-01-09
BR9916276A (pt) 2001-09-04
HU226586B1 (en) 2009-04-28
IL143761A (en) 2006-08-01
AP1769A (en) 2007-08-22
TWI221418B (en) 2004-10-01
BG105591A (en) 2002-01-31
JP4759141B2 (ja) 2011-08-31
KR100707710B1 (ko) 2007-04-18
EA004502B1 (ru) 2004-04-29
DE69927177D1 (de) 2005-10-13
HK1041645A1 (en) 2002-07-19
OA11728A (en) 2005-02-01
PL196822B1 (pl) 2008-02-29
JP2002532408A (ja) 2002-10-02
EP1140026B1 (en) 2005-09-07
YU41401A (sh) 2003-12-31
HUP0105048A2 (hu) 2002-05-29
CN1195497C (zh) 2005-04-06
NO20012981D0 (no) 2001-06-15
DE69927177T2 (de) 2006-06-08
IL143761A0 (en) 2002-04-21
HK1041645B (zh) 2005-07-29
CA2355077C (en) 2009-05-26
UA73101C2 (en) 2005-06-15
HRP20010446A2 (en) 2002-06-30
ZA200104899B (en) 2002-09-16
BG65500B1 (bg) 2008-10-31
AU770673B2 (en) 2004-02-26
CZ20012157A3 (cs) 2001-09-12
NO20012981L (no) 2001-07-27
PL348233A1 (en) 2002-05-20
EP1140026A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
MEP19408A (en) Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same
JP3504953B2 (ja) 可融性担体を含有する医薬組成物およびその製造方法
CN1025150C (zh) 能延续释放的新药物制剂的制备方法
EE03471B1 (et) Dopamiini agonisti sisaldav farmatseutiline kompositsioon, selle kasutamine ja valmistamismeetod, farmatseutiline produkt ja komplekt ning antatsiidi kasutamine
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
TNSN99191A1 (fr) Derives d'adenine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
KR20170012210A (ko) 유기 화합물
CN1032490A (zh) 新药物制剂及其制备方法
FR2724384B1 (fr) Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament
WO2006032202A1 (fr) Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation
Chen et al. Inflammation‐Responsive Functional Core–Shell Micro‐Hydrogels Promote Rotator Cuff Tendon‐To‐Bone Healing by Recruiting MSCs and Immuno‐Modulating Macrophages in Rats
Priyanka et al. Formulation and evaluation of gel loaded with microspheres of apremilast for transdermal delivery system
EP0759299A1 (en) Potentiation of serotonin response
CN102579365B (zh) 利培酮微球制剂及其制备方法
YU64001A (sh) Jedinjenja betahistina sa kontrolisanim oslobadjanjem
CN116459220A (zh) 昔萘酸普拉克索缓释微球及其制备方法与应用
UY25864A1 (es) Derivados de acetamida antagonistas de receptor de nk1
CA2430707C (en) 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl]-piperazin-1-yl}-2-methyl-4h-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine d2 receptor and the serotonin reuptake site
AU2002250983A1 (en) 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site
EA200700877A1 (ru) Диспергируемая во рту фармацевтическая композиция и способ ее получения
EP4406534A1 (en) Sustained-release injectable composition containing naltrexone and method for preparing same
DZ3040A1 (fr) Benzolactames et thioamides cycliques substitués nouveaux, procédé pour préparation et compositions pharmaceutiques les contenant.
Dajie Preparation of microspheres using pollen as mould and their enzyme-carrying activity.
EP4453292A1 (en) Solution electrospun fibers, compositions comprising the same and a process of manufacturing thereof
WO2018192590A2 (zh) 一种稳定的口服药物组合物及其制备方法